Endometrial Cancer - Pipeline Review, H2 2015

Description: Endometrial Cancer - Pipeline Review, H2 2015

Summary


This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Critical Outcome Technologies Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
Galena Biopharma, Inc.
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc.
ImmunoGen, Inc.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
OncoHoldings, Inc.
Oncothyreon Inc.
Otsuka Holdings Co., Ltd.
Pharma Mar, S.A.
Pharmsynthez
Puma Biotechnology, Inc.
Sanofi
Scancell Holdings Plc
Shenogen Pharma Group Ltd.
Endometrial Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
²¹²Pb-TCMC-Trastuzumab - Drug Profile
ABTL-0812 - Drug Profile
AEZS-125 - Drug Profile
AL-3818 - Drug Profile
ARQ-092 - Drug Profile
AV-203 - Drug Profile
AZD-2014 - Drug Profile
AZD-5363 - Drug Profile
BGB-283 - Drug Profile
buparlisib hydrochloride - Drug Profile
cabozantinib s-malate - Drug Profile
cancer vaccine - Drug Profile
Cell Therapy for Ovarian and Endometrial Cancer - Drug Profile
Cell Therapy to Target HER-2 for Oncology - Drug Profile
CLR-457 - Drug Profile
COTI-2 - Drug Profile
cridanimod - Drug Profile
dalantercept - Drug Profile
EP-200 - Drug Profile
epacadostat - Drug Profile
everolimus - Drug Profile
GALE-301 - Drug Profile
GSK-2636771 - Drug Profile
HO-3867 - Drug Profile
HuMax-TF-ADC - Drug Profile
INCB-54828 - Drug Profile
KM-3174 - Drug Profile
lenvatinib - Drug Profile
lurbinectedin - Drug Profile
LY-3023414 - Drug Profile
mirvetuximab soravtansine - Drug Profile
MK-2206 - Drug Profile
Modi-1 - Drug Profile
Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile
neratinib - Drug Profile
nintedanib - Drug Profile
onapristone ER - Drug Profile
ONCO-101 - Drug Profile
ONT-10 - Drug Profile
OPB-111001 - Drug Profile
Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile
pimasertib hydrochloride + voxtalisib - Drug Profile
sapanisertib - Drug Profile
SAR-408701 - Drug Profile
selinexor - Drug Profile
Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile
SNG-1153 - Drug Profile
SP-2509 - Drug Profile
talazoparib - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
X-480 - Drug Profile
zoptarelin doxorubicin - Drug Profile
Endometrial Cancer - Recent Pipeline Updates
Endometrial Cancer - Dormant Projects
Endometrial Cancer - Discontinued Products
Endometrial Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
List of Tables

- Number of Products under Development for Endometrial Cancer, H2 2015
- Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Development by Companies, H2 2015 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Development by Companies, H2 2015 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2015
- Endometrial Cancer - Pipeline by Ability Pharma, SL, H2 2015
- Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015
- Endometrial Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
- Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
- Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015
- Endometrial Cancer - Pipeline by ArQule, Inc., H2 2015
- Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2015
- Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
- Endometrial Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
- Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
- Endometrial Cancer - Pipeline by Cellceutix Corporation, H2 2015
- Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
- Endometrial Cancer - Pipeline by Eisai Co., Ltd., H2 2015
- Endometrial Cancer - Pipeline by Eli Lilly and Company, H2 2015
- Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Endometrial Cancer - Pipeline by Exelixis, Inc., H2 2015
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H2 2015
Endometrial Cancer - Pipeline by Genmab A/S, H2 2015
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Endometrial Cancer - Pipeline by Gradalis Inc., H2 2015
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H2 2015
Endometrial Cancer - Pipeline by Incyte Corporation, H2 2015
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Endometrial Cancer - Pipeline by Medivation, Inc., H2 2015
Endometrial Cancer - Pipeline by Merck & Co., Inc., H2 2015
Endometrial Cancer - Pipeline by Merck KGaA, H2 2015
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Endometrial Cancer - Pipeline by Novartis AG, H2 2015
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H2 2015
Endometrial Cancer - Pipeline by Oncothyreon Inc., H2 2015
Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Endometrial Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Endometrial Cancer - Pipeline by Pharmsynthez, H2 2015
Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
Endometrial Cancer - Pipeline by Sanofi, H2 2015
Endometrial Cancer - Pipeline by Scancell Holdings Plc, H2 2015
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Endometrial Cancer - Dormant Projects, H2 2015
Endometrial Cancer - Discontinued Products, H2 2015
List of Figures

Number of Products under Development for Endometrial Cancer, H2 2015
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3517333/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Endometrial Cancer - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3517333/
Office Code: SCPLJ5A6

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World